[Immunological profile of lymphoid cells in patients with chronic lymphoid leukemia and immunological complications during the treatment with prednisolone and chlorambucil].
Comparative study of immunological phenotype of lymphoid cells of peripheral blood of patients with chronic lymphoid leukemia (CLL) and immune cytopenia at the treatment with prednisolone and chlorambucil has been carried out. It was shown, that inclusion in the treatment of chlorambucil (chlorambucil + prednisolone) enabled the achievement of remission of immune process at the majority of patients though average duration of remission essentially did not differ. The best clinical result was accompanied by more essential variations of leukemic B-cellular population than during the treatment with prednisolone alone. The reduction of absolute number of lymphocytes in patients with CLL under the treatment with chlorambucil and prednisolone was accompanied by reduction of expression of separate B-cellular antigens of mature cells with minimal signs of their activation. The expediency of a combination of prednisolone with chlorambucil in cases of high leukocytosis and expressed hyperplasia of organs of the limphoid systems.
Lohins'kyĭ
V O
VO
Karol'
Iu S
IuS
Tsiapka
O M
OM
Vyhovs'ka
Ia I
IaI
D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D002462:Cell Membrane / Q000187:drug effects / Q000276:immunology; D002699:Chlorambucil / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D016896:Treatment Outcome
D015703:Antigens, CD; D002699:Chlorambucil; D011239:Prednisolone